P30

Cantaloupe, Inc. Reports Third Quarter Fiscal Year 2024 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Software, Other Retail, Data Management, Technology, Apps, Applications, Online Retail, Retail, Other Technology, Education, Seed, PIN, Sport, ARPU, Depreciation, P30, CHEQ, Tax, Adjustment, COGS, GAAP, Growth, Video game

Cantaloupe, Inc. (Nasdaq: CTLP) (“Cantaloupe” or the “Company”), a leading provider of end-to-end technology solutions for self-service commerce, today reported results for the third quarter ended March 31, 2024.

Key Points: 
  • Cantaloupe, Inc. (Nasdaq: CTLP) (“Cantaloupe” or the “Company”), a leading provider of end-to-end technology solutions for self-service commerce, today reported results for the third quarter ended March 31, 2024.
  • “In the third quarter, we reported strong results, reflecting our continued expansion of operating leverage by driving revenue growth while also optimizing COGS and controlling operational expenses.
  • Third Quarter 2024 Business Highlights:
    Active Customers totaled 30,670 at the end of the third quarter of 2024 compared to 27,598 at the end of the third quarter of 2023, an increase of 11.1%.
  • Active Devices totaled 1.22 million at the end of the third quarter of 2024 compared to 1.15 million at the end of the third quarter of 2023, an increase of 5.9%.

Cantaloupe, Inc. Announces Strategic Partnership with Innovative DisplayWorks (IDW) to Manufacture the Cooler Café

Retrieved on: 
Thursday, May 2, 2024
Technology, Payments, Other Retail, Specialty, Software, Food, Beverage, Hardware, Retail, Supply Chain Management, Smart lock, Dumbrell, Partnership, OEM, P30, IDW, Multimedia, Growth, Mobile phone

This partnership involves IDW transforming its standard coolers into smart coolers utilizing Cantaloupe's Smart Lock Connect technology and P30 card readers.

Key Points: 
  • This partnership involves IDW transforming its standard coolers into smart coolers utilizing Cantaloupe's Smart Lock Connect technology and P30 card readers.
  • View the full release here: https://www.businesswire.com/news/home/20240502544035/en/
    Cantaloupe, Inc., a leading provider of end-to-end technology solutions for self-service commerce, announced that the company has entered a strategic partnership with Innovative DisplayWorks (IDW), based in California, to become a preferred original equipment manufacturer (OEM) to manufacture its revolutionary Cooler Café for IDW’s customers across the country.
  • This partnership involves IDW transforming its standard coolers into smart coolers utilizing Cantaloupe's Smart Lock Connect technology and P30 card readers.
  • Cantaloupe’s Smart Lock technology will be seamlessly housed inside the IDW cooler or freezer unit, creating a modern and aesthetically pleasing design.

Cantaloupe, Inc., to Showcase CHEQ and New Innovative Micro Market and Smart Cooler Technology at the NAMA 2024 Show

Retrieved on: 
Tuesday, April 30, 2024
Data Management, Other Retail, Supply Chain Management, Consumer Electronics, Technology, Specialty, Retail, Software, Artificial Intelligence, Internet, Hardware, Sale, CMO, Smart, Seed, POS, Point, AI, Data, Partnership, P30, IDW, CHEQ, Acquisition, Multimedia, P100, P66, NAMA

Cantaloupe will be showcasing its cutting-edge solutions, including the highly anticipated CHEQ point-of-sale (POS) platform, which features a mobile-first approach to accepting payments.

Key Points: 
  • Cantaloupe will be showcasing its cutting-edge solutions, including the highly anticipated CHEQ point-of-sale (POS) platform, which features a mobile-first approach to accepting payments.
  • As a leader in mobile-first payments, CHEQ enables seamless mobile ordering, convenient mobile pick-up points (CHEQ Points), and innovative express kiosks (CHEQ Zones).
  • In Cantaloupe’s booth, guests will experience a full line-up of smart cooler technology, including the Cooler Cafe, with Cool Blu and IDW coolers, and the Smart Café.
  • The Smart Café, is equipped with AI dynamic camera vision technology, further enhancing security and the ultimate convenience for consumers.

Announcing Cantaloupe LIVE, an Interactive Customer Event in Mexico City on 5 December!

Retrieved on: 
Thursday, November 16, 2023
Software, Supply Chain Management, Other Retail, IOT (Internet of Things), Payments, Consumer, Convenience Store, Technology, Food, Beverage, Retail, Other Consumer, Other Technology, P30, Cantaloupe, Inc., Smart lock, Cooler, Age verification system, RSVP, Temperature, Telemetry, Cantaloupe

Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is showcasing its full suite of solutions for the Latin America market at Cantaloupe LIVE on 5 December 2023 in Mexico City.

Key Points: 
  • Cantaloupe, Inc. (NASDAQ: CTLP), a digital payments and software services company that provides end-to-end technology solutions for self-service commerce, is showcasing its full suite of solutions for the Latin America market at Cantaloupe LIVE on 5 December 2023 in Mexico City.
  • Retailers, convenience store operators, equipment manufacturers, entertainment and sports merchandisers, as well as micro market and vending operators, are all invited to attend!
  • The evening reception begins at 4:00 p.m. Those interested in attending should rsvp at https://go.cantaloupe.com/Cantaloupe-Live-Mexico-2023.html .
  • Guests will also experience the Cantaloupe Go line of solutions built specifically for Mexico and other Latin America markets.

Wistar Researchers Discover Possible New Treatment for Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, September 19, 2023
TNBC, CRISPR, PBCC, Cell biology, University, Molecule, Nature Cancer, ACSS2, Culture, Genomics, DP2, HER2, Wistar, Breast, Infection, HIC, Cancer, Biomedical Research, Immunity, Jim Valvano, Research, Zhug, Bangladesh Technical Education Board, Ellen, National Cancer Institute, Triple-negative breast cancer, Patient, Metabolism, Wistar Institute, Immune system, University of Bologna, NCI, P30, NIH, Breast cancer, Vaccine

Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.

Key Points: 
  • Schug’s paper — titled, “Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer” — demonstrates a double-acting mechanism for fighting a particularly aggressive, difficult-to-treat form of breast cancer.
  • Triple-negative breast cancer, or TNBC, affects 10-15% of patients with breast cancer in the US.
  • The absence of any of these receptors — receptors that, when present in other forms of breast cancer, can be effectively targeted during treatment — makes treating TNBC quite difficult, and patients with TNBC have limited treatment options.
  • TNBC’s notorious aggression makes the technical challenge of finding a reliably effective treatment target all the more serious: compared to other breast cancers, TNBC grows faster and resists treatment more stubbornly.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease

Retrieved on: 
Thursday, January 5, 2023
Liver cancer, Fibrosis, Cancer, Icahn School of Medicine at Mount Sinai, Fatty liver disease, Cirrhosis, Mouse, Protein, Weizmann Institute of Science, Lung, Research, Scar, Type 2 diabetes, Institute of Liver and Biliary Sciences, NTRK3, NASH, University of California, Glass, Division, NAFLD, Non-alcoholic fatty liver disease, Liver failure, Disease, Hepatic stellate cell, Tissue, Yale School of Medicine, Liver disease, Patient, Mount Sinai, Science Translational Medicine, Heart, University, Hypertension, University of Edinburgh, Hepatitis, P30, Doctor of Philosophy, Sammi, Cell, Liver, Therapeutic discovery project, Medical imaging, Pharmaceutical industry, Dietary supplement, MD, Medicine

NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai.

Key Points: 
  • Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances.
  • NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • They identified a shared number of 68 pairs of potential drug targets across the two species.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Retrieved on: 
Monday, November 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Science, Biotechnology, Other Technology, Health, Other Science, U.S. News & World Report, Hospital, NCI, MD Anderson Cancer Center, Anderson, SEC filing, IACS, Drug development, Therapy, Patient, P30, Science, News, Precision medicine, Medicine, Cancer, Deep learning, Research, Security (finance), Physician, Risk, Annual report, Monroe Dunaway Anderson, Education, University, COVID-19, Drug discovery, Judgement, Therapeutic discovery project, Artificial intelligence, Global Monitoring Plan, National Cancer Institute, MD, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
  • Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics.
  • We are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments.
  • Under the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.

AB Capital Group Chooses Innovative SS&C Platform to Propel Business

Retrieved on: 
Monday, November 21, 2022
Cloud, P30, SS&C, SS, Senior, Architecture, Software, Wealth, Name, Capital Group Companies, Multimedia, SS&C Technologies, ABS Capital Partners, Risk, Aloha, Trust, ABOR, Bank, Management, Online shopping

WINDSOR, Conn., Nov. 21, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced AB Capital Group has chosen the new innovative platform SS&C Aloha to advance its investment operations, revamp core infrastructure and support its growth objectives.

Key Points: 
  • AB Capital Group manages P30 billion in equity, balanced and money market funds, and segregated investment and trust accounts.
  • "We aim to redefine and advance the wealth experience here in the Philippines with our new Private Wealth group," said Chrissi Morillo, Managing Director, AB Capital Private Wealth.
  • A boutique financial services provider, AB Capital Group focuses on wealth management, trust services, investment banking, and stock market investing.
  • The Group consists of: AB Capital Securities, Inc., one of the oldest and most trusted stock broking names in the industry; AB Capital Asset Management and Trust, with P30 billion in equity, balanced and money market funds under management; AB Capital Investment Banking, providing cutting-edge advice to corporations; and AB Capital Private Wealth, offering bespoke and expert solutions to the wealth journey of high-net-worth clients.